10.06.2024 15:30:11 - dpa-AFX: Abbott's Lingo, Libre Rio OTC Continuous Glucose Monitoring Systems Gets FDA Clearance

NORTH CHICAGO (dpa-AFX) - Abbott Laboratories (ABT) Monday announced FDA
clearance for two new over-the-counter continuous glucose monitoring systems -
Lingo and Libre Rio.

Abbott said, these two systems are based on its FreeStyle Libre continuous
glucose monitoring technology.

Lingo is a consumer biowearable and is designed for general consumers who are
looking to improve their overall health and wellness, while Libre Rio is
designed for adults with Type 2 diabetes, who do not use insulin and manage
diabetes through lifestyle modifications.

The Lingo system combines a biosensor that is worn on the upper arm for 14 days.
Libre Rio is the first over-the-counter continuous glucose monitoring system
with a measurement range of 40-400 mg/dL.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX
Name WKN Börse Kurs Datum/Zeit Diff. Diff. % Geld Brief Erster Schluss
Abbott Laboratories 850103 NYSE 103,910 28.06.24 03:01:10 -0,740 -0,71% 103,700 104,810 104,700 103,910

© 2000-2024 DZ BANK AG. Bitte beachten Sie die Nutzungsbedingungen | Impressum
2024 Infront Financial Technology GmbH